中信证券股份有限公司 关于大博医疗科技股份有限公司 2024 年度募集资金年度存放与使用情况的专项核查报告 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为大博医 疗科技股份公司（以下简称"大博医疗"或"公司"）2020 年度非公开发行 A 股股票的保荐人，根据《证券发行上市保荐业务管理办法（2023 年修订）》《深 圳证券交易所股票上市规则（2024 年修订）》《深圳证券交易所上市公司自律监 管指引第 1 号——主板上市公司规范运作（2023 年 12 月修订）》和《上市公司 监管指引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年修订）》 等文件的相关要求，对大博医疗 2024 年度募集资金年度存放与使用的相关情况 进行了核查，具体如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 根据《上市公司自律监管指引第 1 号——主板上市公司规范运作》相关规 定，节余资金（包括利息收入）低于五百万元或者低于项目募集资金净额 1%的， 可以豁免董事会、股东大会等审议程序，其使用情况应当在年度报告中披露。本 次募集资金专户所存放的募集资金已按规定用途使用完毕。为规范募集资金 ...

Dividend Distribution - The company plans to distribute a cash dividend of 5 RMB per 10 shares to all shareholders, with no bonus shares issued[5] - A cash dividend of CNY 2.5 per 10 shares was distributed, totaling approximately CNY 1.04 billion, which is 175.51% of the net profit for 2023[57] - The company plans to distribute a cash dividend of CNY 5 per 10 shares for the 2024 fiscal year, totaling around CNY 2.03 billion[57] - The total cash dividend, including other methods such as share buybacks, amounted to 438,236,334.87 CNY, representing 100% of the total distributable profit of 1,529,141,179.64 CNY[166] Financial Performance - The company reported a significant increase in revenue, with a year-over-year growth of 15% in the last fiscal year[15] - The company's operating revenue for 2024 reached ¥2,135,559,372.81, representing a 39.29% increase compared to ¥1,533,121,281.80 in 2023[21] - Net profit attributable to shareholders for 2024 was ¥356,803,430.03, a significant increase of 505.16% from ¥58,972,461.01 in 2023[21] - The net profit after deducting non-recurring gains and losses was ¥285,403,513.61, reflecting a 2,603.93% increase from ¥10,555,124.81 in 2023[21] - The net cash flow from operating activities for 2024 was ¥442,300,420.61, up 498.58% from ¥73,861,966.30 in 2023[21] - Basic and diluted earnings per share for 2024 were both ¥0.86, marking a 514.29% increase from ¥0.14 in 2023[21] - The gross profit margin for the reporting period was 68.75%[54] Market Expansion and Strategy - The company is focusing on expanding its market presence, particularly in Southeast Asia, aiming for a 20% increase in market share by 2025[15] - New product development is underway, with three innovative medical devices expected to launch in Q3 2025, projected to contribute an additional 10% to annual revenue[15] - The company has successfully completed two strategic acquisitions in the past year, enhancing its product portfolio and distribution capabilities[15] - The company plans to leverage national policy directions and market trends to enhance its competitive capabilities and capitalize on procurement opportunities[34] - The company is committed to increasing its market share in artificial joint products, which are the fastest-growing segment in the orthopedic implant market[103] Research and Development - The company is investing heavily in R&D, with a budget increase of 25% for the upcoming fiscal year, targeting advancements in minimally invasive surgical technologies[15] - Research and development investment reached ¥306,869,754.43 in 2024, an increase of 7.57% from ¥285,275,500.97 in 2023, representing 14.37% of total operating revenue[79] - The number of R&D personnel increased by 10.45% to 835 in 2024, while the proportion of R&D personnel to total staff slightly decreased to 18.54%[79] - The company has a complete and independent research and development system, with the ability to operate independently in the market[128] Risk Management - The company has identified key risks for future growth, including regulatory changes and supply chain disruptions, and has outlined mitigation strategies[5] - The company faces risks from industry policy changes, foreign business operations, and product development, and will adjust its strategies accordingly[108][109] Corporate Governance - The company has established a "Quality and Return Improvement" action plan to enhance corporate governance and investor communication[114] - The company has held three shareholder meetings during the reporting period, ensuring compliance with legal and regulatory requirements[119] - The board of directors consists of 7 members, including 3 independent directors, complying with the requirements of the China Securities Regulatory Commission[121] - The company has established various internal systems for information disclosure, ensuring compliance with relevant laws and regulations[126] Environmental Responsibility - The company is committed to environmental protection and sustainable development, advocating for resource conservation and low pollution practices in its operations[195] - The company has implemented measures to ensure that all emissions are within the required standards, with no exceedances reported[188] - The company has established a comprehensive pollution prevention and control system, ensuring compliance with environmental regulations[189] Employee Management - The company has a competitive salary policy, ensuring that at least 20% of the distributable profits are allocated for cash dividends if conditions are met[161] - The company has implemented a stock option incentive plan to enhance employee motivation and align interests with shareholders[158] - The company has a structured training program aimed at developing talent and ensuring a smooth integration of new employees[159] Shareholder Relations - The company emphasizes the importance of intellectual property rights, which are crucial for maintaining competitive advantage in the orthopedic medical device market[110] - The company is committed to improving information disclosure quality and strengthening investor relations to promote long-term sustainable development[116] - The company has accumulated cash dividends of approximately 311 million yuan from 2021 to 2023, accounting for about 37.66% of the net profit attributable to shareholders during the same period[115]

A股创新药板块上扬，润都股份、江苏吴中涨停，健友股份涨超6%，康辰药业、贝达药业等跟涨。 ...

大博医疗科技股份有限公司的主营业务为医用高值耗材的生产、研发与销售。主要产品为骨科创伤类植 入耗材、脊柱类植入耗材、关节类植入耗材、运动医学及神经外科类植入耗材、微创外科类耗材、口腔 种植类植入耗材。 最新一期业绩显示，2024年三季报，公司实现营业收入15.29亿元，同比35.88%；净利润2.40亿元，同 比145.48%，销售毛利率68.47%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)103大博医疗68.26232.804.34137.29亿行业平均 45.9448.384.71101.41亿行业中值29.6428.792.3545.52亿1天益医疗-2672.56-2672.561.6719.88亿2硕世生 物-1835.15-1835.151.1537.91亿3诺唯赞-549.11-549.112.5299.35亿4博晖创新-335.30-206.443.6951.46亿5康 泰医学-262.5830.812.6851.07亿6华大基因-197.28215.792.04200.47亿7奥精医疗-108.26-108.261.3819.61亿 8睿昂基因-79.59-79.591.24 ...

Core Viewpoint - The orthopedic implant medical device market in China is experiencing continuous growth, driven by an aging population, increased traffic accidents, and a rising demand for quality health care. The market size has expanded from 36.7 billion RMB in 2020 to 54.8 billion RMB in 2023, with projections to reach 59.2 billion RMB in 2024 [1][10]. Industry Definition and Classification - Orthopedic implant medical devices are surgical instruments implanted in the human body to replace, support, fix, or enhance bone, joint, and spinal tissues, aimed at restoring or improving bone function, promoting healing, alleviating pain, and enhancing the quality of life [2]. Industry Chain Analysis - The industry chain includes upstream raw material supply, midstream manufacturing, and downstream consumer demand. Upstream materials include metals, inorganic non-metals, polymers, and carbon materials, with a gradual increase in domestic supply. Midstream companies manufacture various orthopedic implants, while downstream distributors deliver products to medical institutions [4]. Industry Development History - The development of the orthopedic implant medical device industry in China can be divided into four stages: the embryonic period (early 20th century), the initial period (post-1949 to mid-1980s), the rapid development period (mid-1980s to early 21st century), and the market expansion and import substitution period (early 21st century to present) [6]. Current Industry Development Status - By the end of 2024, the population aged 65 and above in China is expected to reach 220 million, marking a significant increase in demand for orthopedic implants, particularly in the spinal and joint implant sectors [8][10]. Market Segmentation - The market segmentation shows that trauma products account for 38%, joint products 32%, spinal products 23%, and sports medicine products 5%. The trauma segment benefits from widespread applications in treating common orthopedic conditions, while the joint segment is driven by the aging population and increasing joint disease prevalence [12]. Key Companies Analysis - The competitive landscape features several key players: - Weigao Orthopedics offers a wide range of products across various orthopedic fields and emphasizes innovation [14]. - Spring Medical focuses on joint products and is expanding its business [14]. - Dabo Medical excels in trauma products and is venturing into other areas [14]. - Sanyou Medical specializes in spinal products and is extending its product line [14]. - Kelly Tai is focused on minimally invasive spinal products [14]. - Aikang Medical is known for its innovations in joint products [14]. Future Development Trends - The industry is expected to see accelerated import substitution, with domestic companies closing the technology gap with foreign brands and gaining market share due to cost advantages and better local service [19]. - Product innovation is increasing, driven by advancements in clinical medicine and materials science, leading to the development of smaller, more precise implants and the use of new materials [20][21]. - Research on bioactive materials is gaining momentum, with a focus on materials that promote bone growth and healing, enhancing the performance and stability of orthopedic implants [22].

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Dabo Medical (002901), indicating a positive trend in stock price and significant inflow of funds from institutional and retail investors [1][2] - As of April 14, 2025, Dabo Medical's stock closed at 34.68 yuan, reflecting a 2.15% increase, with a trading volume of 21,000 hands and a total transaction amount of 73.0651 million yuan [1] - The net inflow of funds on April 14, 2025, was 372.74 thousand yuan from institutional investors, accounting for 5.1% of the total transaction amount, while retail investors experienced a net outflow of 904.27 thousand yuan, representing 12.38% of the total [1] Group 2 - Dabo Medical's total market capitalization is 14.358 billion yuan, which is higher than the industry average of 10.282 billion yuan, ranking 16th out of 121 in the medical device industry [2] - The company's net profit for the third quarter of 2024 was 240 million yuan, showing a year-on-year increase of 145.48%, with a significant rise in quarterly revenue to 565 million yuan, up 50.38% year-on-year [2] - Dabo Medical's gross profit margin stands at 68.47%, significantly above the industry average of 52.99%, indicating strong profitability compared to its peers [2]

4月10日，大博医疗今日收盘33.75元，上涨2.43%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到69.47倍，总市值139.73亿元。 大博医疗科技股份有限公司的主营业务为医用高值耗材的生产、研发与销售。主要产品为骨科创伤类植 入耗材、脊柱类植入耗材、关节类植入耗材、运动医学及神经外科类植入耗材、微创外科类耗材、口腔 种植类植入耗材。 最新一期业绩显示，2024年三季报，公司实现营业收入15.29亿元，同比35.88%；净利润2.40亿元，同 比145.48%，销售毛利率68.47%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)103大博医疗69.47236.944.42139.73亿行业平均 46.1548.384.77102.50亿行业中值29.1329.012.3143.45亿1硕世生物-1773.70-1773.701.1136.64亿2诺唯 赞-508.88-508.882.3392.08亿3博晖创新-340.62-209.723.7552.28亿4康泰医学-270.0231.682.7652.52亿5华 大基因-198.46217.092.05201.67亿6奥精 ...

证券代码：002901 证券简称：大博医疗 公告编号：2025-012 大博医疗科技股份有限公司 2025 年第一次临时股东大会决议公告 一、会议的召开和出席情况 （一）会议召开情况 1、会议召开的日期、时间： （1）现场会议召开时间：2025 年 4 月 9 日（星期三）下午 14:30 （2）网络投票时间： ①通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 4 月 9 日上 午 9:15-9:25、9:30-11:30，下午 13:00-15:00。 ①通过深圳证券交易所互联网投票系统投票的开始时间为 2025 年 4 月 9 日 上午 9:15 至下午 15:00 期间的任意时间。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 2、现场会议股东出席情况 2、会议召开方式：本次股东大会采用现场表决与网络投票相结合的方式召 开。 3、会议召集人：公司董事会 4、会议主持人：公司董事长林志雄先生主持会议。 1 5、现场会议地点： 厦门市海沧 ...

福建天衡联合律师事务所 关于大博医疗科技股份有限公司 2025 年第一次临时股东大会的 法律意见书 中国﹒厦门 厦禾路 666 号海翼大厦 A 幢 16-18 楼 厦门·上海·福州·泉州·龙岩 http://www.tenetlaw.com 福建天衡联合律师事务所 法律意见书 关于大博医疗科技股份有限公司 2025 年第一次临时股东大会的 法律意见书 致：大博医疗科技股份有限公司 根据中国证券监督管理委员会发布的《上市公司股东会规则》（以下简称《股 东会规则》）的要求，福建天衡联合律师事务所（以下简称"本所"）接受大博 医疗科技股份有限公司（以下简称"大博医疗"或"公司"）的委托，指派律师 （以下简称"本所律师"）出席大博医疗 2025 年第一次临时股东大会（以下简 称"本次股东大会"），对本次股东大会的召集与召开程序、出席会议人员与召 集人的资格、表决程序与表决结果等重要事项出具法律意见。 本所及本所律师依据《中华人民共和国证券法》（以下简称《证券法》）、 《律师事务所从事证券法律业务管理办法》和《律师事务所证券法律业务执业规 则（试行）》等规定及本法律意见书出具日以前已经发生或者存在的事实，严格 履行了法 ...

Group 1 - The core viewpoint of the news is that Dabo Medical's stock performance shows a significant increase in net profit and revenue, despite a high PE ratio compared to industry averages [1] - As of April 2, Dabo Medical's closing price was 35.82 yuan, with a PE ratio of 73.73, marking a new low in 44 days, and a total market capitalization of 14.83 billion yuan [1] - The medical device industry has an average PE ratio of 46.88, with a median of 33.67, placing Dabo Medical at the 103rd position in the industry ranking [1][2] Group 2 - Dabo Medical's main business includes the production, research, and sales of high-value medical consumables, with key products in orthopedic trauma, spinal, joint, sports medicine, neurosurgery, minimally invasive surgery, and dental implants [1] - The latest financial results for the third quarter of 2024 show that the company achieved a revenue of 1.529 billion yuan, a year-on-year increase of 35.88%, and a net profit of 240 million yuan, a year-on-year increase of 145.48%, with a gross profit margin of 68.47% [1]